Sage Therapeutics 进行重组，裁员 33% 以专注于 Zurzuvae 的上市和药物管道。 Sage Therapeutics restructures, laying off 33% workforce for Zurzuvae launch and drug pipeline focus.

Sage治疗机构正在进行重大改组,解雇了165名雇员,约占其劳动力的33%,重点是推出其产后抑郁药Zurzuvae。 Sage Therapeutics is undergoing a major restructuring, laying off over 165 employees, about 33% of its workforce, to focus on the launch of its postpartum depression drug, Zurzuvae. 该公司的目标是改善其财务稳定,并在临床试验中遭遇挫折后优先考虑其药物开发管道. The company aims to improve its financial stability and prioritize its drug development pipeline following setbacks in clinical trials. 预计到2024年底这些变化将完成,将有助于将Sage定位为长期增长。 The changes are expected to complete by the end of 2024 and will help position Sage for long-term growth.